Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran.
Medical Branch, Islamic Azad University of Tehran, Tehran, Iran.
Cell Mol Life Sci. 2023 Mar 22;80(4):104. doi: 10.1007/s00018-023-04729-4.
Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.
靶向治疗是一种新的癌症治疗方法,涉及专门针对癌细胞中特定蛋白质的药物,例如受体酪氨酸激酶(RTKs),它们参与促进生长和增殖,因此抑制这些蛋白质可能会阻碍癌症的进展。对 RTKs 和相关信号级联的理解,使许多使用 RTK 抑制剂(RTKI)的靶向药物治疗得以发展,其中一些已经进入临床应用。在这里,我们讨论 RTK 的结构、激活机制和功能。此外,我们还介绍了联合药物治疗(包括一种 RTKI 或多种 RTKIs 与化疗或免疫治疗药物联合使用)的潜在影响,特别是针对耐药性癌症。